|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
We prospectively enrolled 25 HIV-infected children to study HIV-, cytomegalovirus (CMV)-, and tuberculosis (TB)-specific T-cell responses before and 1 year after initiation of ART using intracellular cytokine (interleukin-2, interferon-γ, tumor necrosis factor-α) staining assays after in vitro stimulation.
|
30624717 |
2019 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
The magnitude of the CD4 IL-2 response significantly predicted onset of frailty in HIV- nonfrail men, but not in HIV+ nonfrail men.
|
29529309 |
2018 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Randomized controlled trials (RCTs) that evaluated the effects of IL-2 as an adjunct to ART in reducing the morbidity and mortality in HIV-positive adults.
|
28542796 |
2017 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
The molecular mechanisms for IL2 gene-specific dysregulation during chronic human immunodeficiency virus type 1 (HIV-1) infection are unknown.
|
25001463 |
2015 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
In each, patients infected with the human immunodeficiency virus (HIV) who had CD4+ cell counts of either 50 to 299 per cubic millimeter (SILCAAT) or 300 or more per cubic millimeter (ESPRIT) were randomly assigned to receive interleukin-2 plus antiretroviral therapy or antiretroviral therapy alone.
|
19828532 |
2009 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human immunodeficiency virus type 1 escapes from interleukin-2-producing CD4+ T-cell responses without high-frequency fixation of mutations.
|
19553327 |
2009 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, certain HLA class I alleles are enriched in HIV controllers and are associated with strong Gag-specific CD8(+)IFN-gamma(+)IL-2(+) T cells.
|
18353945 |
2008 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Monocyte-derived DC, from therapy-naïve and HAART-treated HIV-1-seropositive subjects, that were electroporated with consensus codon-optimized HxB2 gag mRNA efficiently expanded T cells, secreting gamma interferon (IFN-gamma) and interleukin 2 (IL-2), as well as other cytokines and perforin, upon restimulation with a pool of overlapping Gag peptides.
|
18234800 |
2008 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cryptococcal killing by CD4+ T cells was defective in human immunodeficiency virus (HIV)-infected patients due to dysregulated granulysin and perforin production in response to IL-2 or anti-CD3 + IL-2.
|
17038537 |
2007 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
These defective proliferative responses of HIV- and CMV-specific CD8+ T cells were restored by the addition of IL-2 at the time of stimulation.
|
16847956 |
2006 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, 80% of HIV-specific CD4+ T cells expressed high levels of the negative regulator CTLA-4 in response to antigen stimulation in vitro, which was probably contributing to their inability to produce interleukin-2 and proliferate.
|
17005693 |
2006 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, these data indicate that nasal vaccination with SHIV-DNA plus IL-2/Ig DNA and rMVA can provide significant protection from disease progression.
|
15004179 |
2004 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
No significant changes were observed in HIV viral load, CD3 and CD8 lymphocyte counts, expression of interleukin 2 receptor and CXCR4, or gene expression of CCR5 and beta-chemokines 48 hours after vaccination.
|
15478388 |
2004 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thirty patients with acute human immunodeficiency virus (HIV) type 1 infection received a combination of 3 antiretroviral drugs (n=15) or 4 antiretroviral drugs plus hydroxyurea and interleukin-2 (n=15) for 24 months, followed by 1-3 structured therapeutic interruptions (STIs).
|
14624367 |
2003 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
On the other hand, IL-2 stimulation of MDDCs dramatically increased HIV-1 replication and this effect was highly evident on low-replicating, CXCR4-dependent isolates.
|
12699419 |
2003 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
The co-transfection of both plasmids was comparable to a single transfection of pHIV-IL-2-neo-C-Tat in both high and low transfection efficiency cells.
|
12449396 |
2002 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Despite the incomplete suppression of viral replication, IL-2 with ART did not increase either plasma viremia or cell-associated HIV DNA levels.
|
11319683 |
2001 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus: (1) T-cell proliferation to HIV-specific and HIV-unrelated antigens is potent in antiretroviral-naive but suppressed in HAART-treated individuals; (2) interleukin-(IL)2, IL-12 and interferon gamma (IFNgamma) production is robust in naive patients; and (3) a high CCR5/low CXCR4 pattern of HIV coreceptors-specific mRNA is observed in naive but not in HAART-treated patients.
|
10708280 |
2000 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effects of subcutaneous interleukin-2 therapy on phenotype and function of peripheral blood mononuclear cells in human immunodeficiency virus infected patients.
|
10722371 |
2000 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interleukin 2 safety and differential effects on CD4 cell counts, CD4 cell percentages, and plasma HIV RNA levels.
|
10889591 |
2000 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Thus, intermittent IL-2 does not result in sustained increases in either plasma or tissue levels of HIV and does not result in sustained expression of a previously silent quasi species.
|
10979900 |
2000 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Twenty-four HIV-positive subjects received a single infusion of 2 to 3 x 10(10) autologous CD4zeta-modified CD4(+) and CD8(+) T cells administered with (n = 11) or without (n = 13) interleukin-2 (IL-2).
|
10910888 |
2000 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
Biomarker
|
disease |
BEFREE |
gp41 envelope protein of human immunodeficiency virus induces interleukin (IL)-10 in monocytes, but not in B, T, or NK cells, leading to reduced IL-2 and interferon-gamma production.
|
9534962 |
1998 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The dominant defect in HIV-infected children appears to be one of reduced type 1 cytokines, predominantly IL-2.
|
8985195 |
1997 |
|
Human immunodeficiency virus (HIV) II infection category B1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In an attempt to restore immune competence to 12 human immunodeficiency virus-1 (HIV-1)-infected patients, lymphocytes from their HIV-1-uninfected identical twin siblings were cultured in medium supplemented with 5% fetal calf serum (FCS), anti-CD3 antibody, and interleukin-2 (100 IU/mL) for 10 days and then infused into the patients.
|
9028307 |
1997 |